Literature DB >> 20333681

Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers.

Shinya Hayami1, John D Kelly, Hyun-Soo Cho, Masanori Yoshimatsu, Motoko Unoki, Tatsuhiko Tsunoda, Helen I Field, David E Neal, Hiroki Yamaue, Bruce A J Ponder, Yusuke Nakamura, Ryuji Hamamoto.   

Abstract

A number of histone demethylases have been identified and biochemically characterized, but the pathological roles of their dysfunction in human disease like cancer have not been well understood. Here, we demonstrate important roles of lysine-specific demethylase 1 (LSD1) in human carcinogenesis. Expression levels of LSD1 are significantly elevated in human bladder carcinomas compared with nonneoplastic bladder tissues (p < 0.0001). cDNA microarray analysis also revealed its transactivation in lung and colorectal carcinomas. LSD1-specific small interfering RNAs significantly knocked down its expression and resulted in suppression of proliferation of various bladder and lung cancer cell lines. Concordantly, introduction of exogenous LSD1 expression promoted cell cycle progression of human embryonic kidney fibroblast cells. Expression profile analysis showed that LSD1 could affect the expression of genes involved in various chromatin-modifying pathways such as chromatin remodeling at centromere, centromeric heterochromatin formation and chromatin assembly, indicating its essential roles in carcinogenesis through chromatin modification.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20333681     DOI: 10.1002/ijc.25349

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  178 in total

1.  Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.

Authors:  Tino Schenk; Weihsu Claire Chen; Stefanie Göllner; Louise Howell; Liqing Jin; Katja Hebestreit; Hans-Ulrich Klein; Andreea C Popescu; Alan Burnett; Ken Mills; Robert A Casero; Laurence Marton; Patrick Woster; Mark D Minden; Martin Dugas; Jean C Y Wang; John E Dick; Carsten Müller-Tidow; Kevin Petrie; Arthur Zelent
Journal:  Nat Med       Date:  2012-03-11       Impact factor: 53.440

Review 2.  Molecular mechanisms and potential functions of histone demethylases.

Authors:  Susanne Marije Kooistra; Kristian Helin
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

3.  Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors.

Authors:  Victor S Gehling; John P McGrath; Martin Duplessis; Avinash Khanna; Francois Brucelle; Rishi G Vaswani; Alexandre Côté; Jacob Stuckey; Venita Watson; Richard T Cummings; Srividya Balasubramanian; Priyadarshini Iyer; Priyanka Sawant; Andrew C Good; Brian K Albrecht; Jean-Christophe Harmange; James E Audia; Steven F Bellon; Patrick Trojer; Julian R Levell
Journal:  ACS Med Chem Lett       Date:  2020-05-06       Impact factor: 4.345

4.  Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures.

Authors:  Shannon L Nowotarski; Boobalan Pachaiyappan; Steven L Holshouser; Craig J Kutz; Youxuan Li; Yi Huang; Shiv K Sharma; Robert A Casero; Patrick M Woster
Journal:  Bioorg Med Chem       Date:  2015-02-07       Impact factor: 3.641

5.  KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family.

Authors:  Zanabazar Enkhbaatar; Minoru Terashima; Dulamsuren Oktyabri; Shoichiro Tange; Akihiko Ishimura; Seiji Yano; Takeshi Suzuki
Journal:  Cell Cycle       Date:  2013-06-06       Impact factor: 4.534

Review 6.  Chromatin proteins and modifications as drug targets.

Authors:  Kristian Helin; Dashyant Dhanak
Journal:  Nature       Date:  2013-10-24       Impact factor: 49.962

7.  CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression.

Authors:  Hung-Chih Hsu; Yi-Shiuan Liu; Kai-Chi Tseng; Tsai-Sheng Yang; Chien-Yuh Yeh; Jeng-Fu You; Hsin-Yuan Hung; Shu-Jen Chen; Hua-Chien Chen
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-25       Impact factor: 4.553

8.  Status of epigenetic chromatin modification enzymes and esophageal squamous cell carcinoma risk in northeast Indian population.

Authors:  Virendra Singh; Laishram C Singh; Avninder P Singh; Jagannath Sharma; Bibhuti B Borthakur; Arundhati Debnath; Avdhesh K Rai; Rup K Phukan; Jagadish Mahanta; Amal C Kataki; Sujala Kapur; Sunita Saxena
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

9.  Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1.

Authors:  Hyun-Soo Cho; John D Kelly; Shinya Hayami; Gouji Toyokawa; Masahi Takawa; Masanori Yoshimatsu; Tatsuhiko Tsunoda; Helen I Field; David E Neal; Bruce Aj Ponder; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Neoplasia       Date:  2011-08       Impact factor: 5.715

10.  Relationship between LSD1 expression and E-cadherin expression in prostate cancer.

Authors:  Min Wang; Xiuheng Liu; Guanjun Jiang; Hui Chen; Jia Guo; Xiaodong Weng
Journal:  Int Urol Nephrol       Date:  2015-01-28       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.